Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1266MR)

This product GTTS-WQ1266MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1266MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11968MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ13046MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5623MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ13873MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ7801MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ11935MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ2143MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ5508MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW